Individualized Diet Elimination Therapy for Eosinophilic Esophagitis

Phase-Based Progress Estimates
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Eosinophilic Esophagitis+2 More
Algorithm to diagnose food allergens - Device
Any Age
All Sexes
What conditions do you have?

Study Summary

This is a randomized, double blind, sham-controlled, pilot/feasibility trial of individualized dietary elimination treatment.

Eligible Conditions

  • EoE
  • Eosinophilic Esophagitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Eosinophilic Esophagitis

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 8 weeks

8 weeks
Dysphagia symptom score
Endoscopic severity
Percentage of Histologic Responders
Post-treatment peak eosinophil count
Baseline and Week 8
Change in peak eosinophil count

Trial Safety

Safety Progress

1 of 3

Other trials for Eosinophilic Esophagitis

Trial Design

2 Treatment Groups

Individualized Diet Elimination Therapy
1 of 2
Sham Diet Elimination Therapy
1 of 2
Experimental Treatment
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Individualized Diet Elimination Therapy · Has Placebo Group · N/A

Individualized Diet Elimination Therapy
Experimental Group · 1 Intervention: Algorithm to diagnose food allergens · Intervention Types: Device
Sham Diet Elimination Therapy
PlaceboComparator Group · 1 Intervention: Sham diet · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
Closest Location: The University of North Carolina at Chapel Hill · Chapel Hill, NC
2012First Recorded Clinical Trial
1 TrialsResearching Eosinophilic Esophagitis
61 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have EoE and symptoms of dysphagia.
You have no prior treatment with, or documented failure of, dietary elimination therapy

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.